PPMI Study Overview
Launched in 2010, the Parkinson’s Progression Markers Initiative (PPMI) is a longitudinal observational study of more than 1,500 participants contributing comprehensive clinical and imaging data and biological samples at 33 clinical sites around the world. Sponsored by The Michael J. Fox Foundation and supported by a number of industry partners, PPMI follows participants for five to 13 years. The study has built a robust database and biorepository, which it makes available to the research community to further biomarker discovery and validation and therapeutic development.
Total Participants (Cohort records that met the AMP PD minimum clinical data criteria):
AMP PD Designation:
Data from the PPMI cohort is designated with the prefix “PP” in the AMP PD Portal. PPMI data in the AMP PD portal includes: Demographics, family history, medication history, MDS-UPDRS, MoCA, WGS, blood transcriptomics
Additional Study Information:
PPMI Study Goals and Objectives
The primary objective of this study is to identify clinical, imaging and biologic markers of PD progression for use in clinical trials of disease-modifying therapies.
The specific aims to accomplish the primary objective are:
Develop a comprehensive and uniformly acquired clinical and imaging dataset and biological samples that can be used to estimate the mean rates of change and the variability around the mean of clinical, imaging and biomic outcomes in early PD patients, prodromal PD subjects, and PD subjects with a LRKK2, GBA or SNCA mutation. Investigate existing and identify novel clinical, imaging, and biomic Parkinson disease progression markers to identify quantitative individual measures or combination of measures that demonstrate optimum interval change in PD patients in comparison to healthy controls, SWEDD subjects, Prodromal subjects, PD subjects with a LRRK2, GBA or SNCA mutation, unaffected LRRK2, GBA or SNCA mutation carriers, or in sub-sets of PD patients defined by baseline assessments, progression milestones and/or rate of clinical, imaging, genetic mutations, or biomic change. Conduct preliminary verification studies on promising biological markers using stored collected samples.
Study Specific Data Contribution
The following variables and associated data are specific to the PPMI study and are available for analysis as part of AMP PD. These variables have not been harmonized across cohorts, but are relevant to Parkinson's Disease research:
|Medical History||PD Surgery (DBS)||Surgery for Parkinson disease|
|Summarized Imaging Data||MRI||MRI results|
|Summarized Imaging Data||DaTSCAN||DaTSCAN SPECT Visual Interpretation Assessment Report|
|Summarized Imaging Data||DTI||DTI Measure (Brain tissue being measured; Left Rostral; Left Middle; Left Caudal; Right Rostral; Right Middle; Right Caudal; Left Reference; Right Reference)|
Tables that Reference these Variables:
- Medical History
- MRI (Magnetic_Resonance_Imaging.csv)
Data Type Information:
|Column Name||Data Type||Unique Values|
|surgery_for_parkinson_disease||STRING||DBS (Deep Brain Stimulation)|
Abnormal, not clinically significant;
Abnormal, clinically significant
PPMI Inclusion and Exclusion Criteria
Subjects with and without Parkinson’s disease who have a genetic mutation in LRRK2, GBA, or SNCA.